| Literature DB >> 34532423 |
Binfeng Yu1, Lini Jin1, Zhouwei Chen2, Wanyun Nie1, Liangliang Chen1, Yanhong Ma1, Huan Chen2, Yawen Wu2, Yunting Ma2, Jianghua Chen1, Fei Han1.
Abstract
BACKGROUND: Microscopic polyangiitis (MPA) is an autoimmune disease characterized by frequent kidney involvement. Imbalance of intestinal flora has been found implicated in multiple immune-mediated disorders. However, the profiling and the role of the gut microbiome in MPA remains unclear.Entities:
Keywords: Microscopic polyangiitis (MPA); anti-neutrophil cytoplasmic antibody (ANCA); diagnosis; gut microbiome; kidney
Year: 2021 PMID: 34532423 PMCID: PMC8422107 DOI: 10.21037/atm-21-1315
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
The clinical characteristics and laboratory results of all enrolled participants (n=105)
| Parameter | HC (n=34) | inMPA (n=36) | aMPA (n=35) |
|---|---|---|---|
| Demographic characteristic | |||
| Age, yr | 58 [53–63] | 61 [55–65] | 61 [55–68] |
| Male, n [%] | 12 [35] | 20 [56] | 19 [54] |
| BMI, kg/m2 | 21.37±2.1 | 22.75±3.76 | 21.70±3.46 |
| Laboratory parameter | |||
| WBC, 1012/L | 5.4±1.1 | 6.8±2.2** | 7.6±2.7** |
| Hb, g/L | 138±18 | 122±20** | 83±18**## |
| PLT, 109/L | 216±42 | 203±54 | 189±90* |
| Scr, mmol/L | 59 [52–66] | 129 [97–167]** | 330 [206–533]**## |
| Up, g/24 h | – | 0.62±0.48 | 2.03±1.21## |
| CRP, mg/L | – | 2.3 [1.1–3.7] | 7.6 [4.0–15.2]## |
| ESR, mm/h | – | 16 [9–30] | 66 [39–97]## |
| ANCA titre, UI/mL | – | 39 [15–57] | 62 [37–97]## |
| BVAS score | – | 0 [0–0] | 16 [13–18]## |
| Disease course [Mo] | 28 [13–51] | Newly diagnosed | |
| Immunosuppressive drugs at sampling, n [%] | |||
| Steroid | – | 25 [69] | 23 [66] |
| MMF | – | 23 [64] | 3 [9]## |
| AZA | – | 4 [11] | 2 [6] |
| CTX | – | 0 [0] | 3 [9] |
| Rituximab | – | 0 [0] | 2 [6] |
*, P<0.05, versus HC; **, P<0.01, versus HC; ##, P<0.01, versus inMPA; Wilcoxon test between any two groups and Kruskal-Wallis test among three groups. Data are expressed as median [IQR], mean [SD], or n [%] as appropriate. aMPA, active microscopic polyangiitis; ANCA, anti-neutrophil cytoplasm antibody; AZA, acetazolamide; BMI, body mass index; BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; CTX, cyclophosphamide; ESR, erythrocyte sedimentation rate; HC, healthy control; Hb, hemoglobin; inMPA, inactive microscopic polyangiitis; MMF, mycophenolate mofetil; PLT, platelet; Scr, serum creatinine; Up, urine protein; WBC, white blood cell.
Figure 1The diversity of gut microbiome in patients with active MPA (aMPA, n=35), inactive MPA (inMPA, n=36) and healthy controls (HCs, n=34). (A) A venn diagram showing overlaps of 1,754 clustered OTUs among the three groups. The α-diversity assessed by richness indices [Ace (B) and Chao1 index (C)] and diversity indices [Simpson (D) and Shannon index (E)] was compared among multiple groups by Kruskal-Wallis (K-W) test and between any two cohorts by Wilcoxon rank sum test. (F) β-diversity, calculated by Non-metric multidimensional scaling (NMDS) (stress=0.18), displayed the dissimilarities in microbial composition of all samples, and illustrated a biased community distribution among different groups. *P<0.05; **P<0.01.
Figure 2Microbial composition and differential bacterial abundance at phylum and genus levels in fecal samples from patients with active MPA (aMPA, n=35), inactive MPA (inMPA, n=36) and healthy controls (HCs, n=34). Top 10 abundant phyla (A) and genera (B) in fecal samples from the three groups. (C) The abundance of significantly different genera between aMPA samples and HC samples. (D) The increased abundance of phyla in inMPA samples versus aMPA. (E) The abundance of significantly different genera between aMPA and inMPA samples. The microbial abundance was compared by Wilcoxon rank sum test and adjusted using Benjamini-Hochberg method. The boxes and lines inside represent the 95% CI and median, respectively.
Figure 3The genus and OTU markers in association with disease-related indices, severity of kidney impairment and renal prognosis. (A) Correlations between the abundance of the 14 markedly altered genera and clinical parameters. The color and area of the pie charts represent the positive (blue) or negative (red) correlation and the scale of correlation coefficient, respectively, and asterisks inside denote “Holm” adjusted P values <0.05. Volcano plots of the differential analysis on OTU abundance of incipient patients with active MPA between those with initial dialysis or not (B) and between those progressing into ESRD or not (C). The red and green points indicate increased and reduced abundance in non-dialysis or non-ESRD group, respectively, that reach a significance difference with unadjusted P values <0.05 by Wilcoxon test. The cut-off of effect size, i.e., the ratio of median difference between two groups and median of the largest difference within two groups, is set to 0.5. An absolute effect size of 0.5 or greater denotes an OTU marker for differentiation of subgroups. ESRD, end-stage renal disease.
Figure 4Gut microbial profiling-based models for diagnosing MPA and predicting disease activity. (A) Plots of five trials of cross-validation (CV) error on random forest models to differentiate patients with active MPA (aMPA, n=35) from healthy controls (HCs, n=34). The optimal set of markers comprises 6 OTUs (pink line). The black curve represents the average CV error of the five trials (grey lines). (B) The predicted probability of MPA significantly higher in aMPA samples than in HCs samples (P=5.7×10–10, Wilcoxon test) in the optimal set of OTUs in A. (C) Receiver operating characteristic curve (ROC) for the selected 6 OTU markers. The AUC is 93.45 and 95% CI is 88.15–98.74%. (D) Plots of cross-validation error on the same model to differentiate Ampa (n=35) from in active MPA (inMPA) (n=36). The optimal set of markers comprises 11 OTUs (pink line). (E) The predicted probability of active disease significantly higher in aMPA samples than in inMPA samples (P=3.8×10–9, Wilcoxon test) in the optimal set of OTUs in D. (F) ROC for the selected 11 OTU markers. The AUC is 90.71 and 95% CI is 88.15–98.74%.